Announcement on Receiving the "Acceptance Notice" for the IND Application of Innovative Drug HSK60002 Tablets

Haisco Pharmaceutical Group Co., Ltd.·July 13, 2026·2 pages

✨ AI Summary

Hansoh Pharmaceutical announced it received an "Acceptance Notice" from the NMPA for its innovative drug HSK60002 tablets IND application. The drug, a Class 1 chemical drug, is a self-developed oral small molecule formulation for treating inflammatory diseases. Preclinical data shows significant efficacy and a clear mechanism of action, indicating good development value and prospects.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Stock Code: 002653

Stock Abbreviation: Hansoh Pharma

Announcement Number: 2026-075

Hansoh Pharmaceutical Group Company Limited

Announcement on Receiving the "Acceptance Notice" for the IND Application of Innovative Drug HSK60002 Tablets

The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and are free from any false records, misleading statements, or material omissions.

Hansoh Pharmaceutical Group Company Limited (hereinafter referred to as the "Company") recently received an "Acceptance Notice" issued by the National Medical Products Administration, the basic situation is as follows:

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.